Eli Lilly and EVA Pharma partner to increase baricitinib access in 49 African countries by 2030 under Lilly's 30x30 plan.

Eli Lilly and EVA Pharma are partnering to increase access to baricitinib, a treatment for various immunological diseases, in 49 low- to middle-income African countries by 2030. This initiative is part of Lilly's 30x30 plan, which aims to enhance healthcare access for 30 million people in resource-limited areas. Lilly will share manufacturing knowledge with EVA Pharma to facilitate local production and distribution of the treatment.

September 04, 2024
6 Articles

Further Reading